Company Overview
Pfizer Inc delivered impressive Q1 2026 earnings on May 6th—six days ago—reporting revenue of $14.9 billion and adjusted earnings per share of $1.23 that crushed analyst expectations of $1.08. Excluding COVID products (vaccine and Paxlovid antiviral), operational revenue grew 11% year-over-year, demonstrating that Pfizer’s underlying business is thriving as the company transitions away from pandemic-era dependence.
What makes Pfizer particularly compelling right now is the oncology franchise strength revealed during the May 6th earnings call. CEO Albert Bourla highlighted that oncology revenue reached $3.8 billion in Q1 (up 25% year-over-year), driven by blockbuster drugs including Ibrance (breast cancer), Xtandi (prostate cancer), Eliquis (blood thinner preventing cancer-related clots), and newer launches like Padcev (bladder cancer) and Tivdak (cervical cancer). Most significantly, Pfizer disclosed encouraging Phase 2 data for danuglipron—its oral obesity drug candidate—showing 15% weight loss at 32 weeks with improved tolerability versus earlier formulations.
Key Technical and Fundamental Drivers
Strong Q1 Beat → May 6th Results
Pfizer reported Q1 2026 results six days ago showing $14.9B revenue, $1.23 adjusted EPS (crushing $1.08 estimates), with operational revenue (ex-COVID) up 11%.
Oncology Surge → $3.8B Quarterly Revenue
Oncology franchise generated $3.8 billion in Q1 (up 25% YoY), driven by blockbusters Ibrance, Xtandi, and fast-growing launches Padcev and Tivdak.
Obesity Drug Progress → 15% Weight Loss Phase 2
Danuglipron oral obesity drug showed 15% weight loss at 32 weeks in Phase 2 with improved tolerability, Phase 3 trials starting Q3 2026.
COVID Overhang Fading → Normalized Comps
COVID vaccine/Paxlovid revenue declining to $2 billion quarterly (from $15+ billion peaks), providing easier year-over-year comparisons as base normalizes.
Dividend Aristocrat → 4.5% Yield
Pfizer offers 4.5% dividend yield with 14 consecutive years of increases, generating over $9 billion in annual shareholder dividends.
Market Takeaway
Pfizer’s May 6th earnings—six days ago—demonstrate a pharmaceutical giant successfully navigating the transition from COVID windfall to diversified growth. The 11% operational revenue growth (excluding COVID products) is the metric investors should focus on, as it reflects Pfizer’s true business performance without pandemic distortions. The oncology franchise growing 25% to $3.8 billion quarterly positions Pfizer as a major cancer treatment player alongside Bristol Myers Squibb, Merck, and Johnson & Johnson.
The oncology portfolio’s strength stems from both blockbuster mature products and newer launches gaining traction. Ibrance (breast cancer) remains a multi-billion dollar franchise despite increasing competition, while Xtandi (prostate cancer, co-marketed with Astellas) continues growing as global diagnosis rates increase. The newer products Padcev (bladder cancer) and Tivdak (cervical cancer)—both acquired through the $43 billion Seagen acquisition in 2023—are ramping faster than expected, with analysts projecting each could reach $3-5 billion in peak annual sales.
The danuglipron obesity data is a potential game-changer that’s flying under the radar. While Eli Lilly and Novo Nordisk dominate obesity drug headlines, Pfizer’s oral candidate achieving 15% weight loss positions it as a dark horse competitor. The oral formulation (pill versus injection) is particularly compelling—surveys show 60-70% of patients prefer pills over weekly injections, creating substantial market opportunity if efficacy matches injectables. The improved tolerability versus earlier danuglipron formulations addresses previous concerns about gastrointestinal side effects that plagued initial trials.
If Phase 3 trials (starting Q3 2026) confirm the Phase 2 results, Pfizer could have an oral obesity drug launching in 2028-2029 into a market projected to exceed $100 billion globally. Even capturing 10-15% share would represent $10-15 billion in peak sales—transformational for Pfizer’s growth profile and enough to rerate the stock significantly.
The COVID product normalization is actually positive for Pfizer’s valuation. At pandemic peaks, COVID vaccine and Paxlovid generated $55+ billion annually, but investors never gave Pfizer credit for this revenue, treating it as temporary windfall. Now that COVID products have declined to $8-10 billion annually (and stabilizing at that level as endemic disease), year-over-year comparisons become much easier. Going forward, all growth comes from operational businesses rather than being obscured by COVID declines.
The 4.5% dividend yield is among the highest in large-cap pharma, providing substantial income while investors wait for the growth story to unfold. Pfizer generates $12+ billion in annual free cash flow, easily covering the $9 billion dividend while funding R&D and bolt-on acquisitions. The company’s commitment to maintaining and growing the dividend—14 consecutive years of increases—provides downside protection as income-focused investors support the stock.
The patent cliff concerns that have plagued Pfizer for years are largely behind it. Lipitor (cholesterol drug) lost patent protection over a decade ago, and most remaining blockbusters maintain exclusivity through 2028-2030. The Seagen acquisition filled the pipeline with oncology assets, while internal R&D is producing promising candidates in obesity, rare diseases, and infectious diseases beyond COVID.
Trading at depressed valuations around 9-10x forward earnings with a 4.5% yield, 11% operational growth, and obesity drug optionality, Pfizer offers deep value in large-cap pharma. The market is treating Pfizer as a mature low-growth dividend stock, but if oncology momentum continues and danuglipron succeeds in Phase 3, the earnings growth could surprise significantly positive, driving multiple expansion toward 12-15x that peer pharma companies with similar profiles command.